Hot Topics in Drug Product Process Validation: A Reviewer s Perspective
|
|
- Amberly Rose
- 6 years ago
- Views:
Transcription
1 Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum Gaithersburg, MD - July 2016 Drug Product Validation Session 1
2 Presentation Outline Quality microbiology content of BLA submissions Guidance documents and regulations Process validation: common deficiencies and case studies Sterilizing filtration Post-reconstitution and post-dilution storage Media fills Conclusions and reference slides Drug product quality micro content for CDER BLAs 2
3 Laws and Regulations Public Health Service Act Section 351 (a)(2)(c) -- Licensure of biological establishments and products The biological product must be safe, pure and potent The facility in which the biological product is manufactured, processed, packed, or held must meet standards designed to assure that the biological product continues to be safe, pure and potent Federal Food, Drug, and Cosmetic (FD&C) Act (1938, 1962, 1997, 2007) Interprets that biological products are also drugs The FFD&C Act applies to a biological product, except no application required under section 505 Inspection under both the provisions of both the PHS Act and the FD&C Act Both the PHS and FD&C Acts require that biological products must be manufactured under CGMP as described in 21 CFR 210 and 211 and
4 Laws and Regulations (cont.) Validation of aseptic and sterilization processes: 21 CFR Control of microbiological contamination (b) Appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, shall be established and followed. Such procedures shall include validation of all aseptic and sterilization processes. Addresses the validation of aseptic and sterilization processes Refer to 21 CFR Part 211 for additional regulations applicable to sterile drug products. 4
5 BLA Content: Guidance for Sterile Drugs Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products (1994) Outlines the sterilization process validation information that should be provided in an application. Referenced for BLAs in the following guidance: Guidance for Industry for the Submission of Chemistry, Manufacturing, and Controls Information for a Therapeutic Recombinant DNA-Derived Product or a Monoclonal Antibody Product for In Vivo Use (1996) 5
6 BLA Content: Guidance for Sterile Drugs (cont.) Sterile Drug Products Produced by Aseptic Processing Current Good Manufacturing Practice (2004) Provides guidance on how to comply with CGMP regulations. Use in conjunction with other compliance programs and guidance. Established Conditions: Reportable CMC Changes for Approved Drug and Biologics Products (2015 draft) 6
7 Common Deficiencies and Case Studies Sterilizing filtration Refer to PDA Technical Report 26 (Sterilizing Filtration of Liquids) for general guidance. Topics: Integrity testing Process parameters Microbial retention validation Post-reconstitution and post-dilution storage Media fills 7
8 Sterilizing Filter Integrity Testing: Common Deficiencies No information or insufficient information for product bubble point determination. Test description missing or insufficient. Acceptance criterion listed only as pass. Wetting agent not specified. Numerical value for pass not provided. Sterilizing filter integrity test results from process validation lots not provided. 8
9 Sterilizing Filtration Parameters: Common Deficiencies Filtration time limit (product contact time): Time limit was not included in parameters. Proposed time limit was significantly longer than required for the production process and was not appropriately validated by the microbial retention study. 9
10 Sterilizing Filtration Parameters: Common Deficiencies (cont.) Pressure or flow rate limit: Peristaltic pump speed range provided in lieu of pressure or flow rate limit. Pump speed should be correlated to a parameter validated by the microbial retention study (flow rate or pressure). Controls should be in place to ensure that the pressure or flow rate limit validated by the microbial retention study is not exceeded during production. 10
11 Sterilizing Filtration Parameters: Case Study Issue: The microbial retention study modeled flow rate and pressure limits for the filtration process, but the production process parameters included peristaltic pump speed range in lieu of flow rate or pressure. Information request: The sterile filtration parameters should include flow rate as validated by the microbial retention study. Peristaltic pump speed is only one factor that contributes to filtration flow rate. Please amend section 3.2.P.3.4 to include the operating range for flow rate. In addition, please provide the maximum flow rates for sterile filtration of the process validation lots. 11
12 Result: Sterilizing Filtration Parameters: Case Study (cont.) The calculated flow rates for the process validation lots were provided. The calculated flow rates were well below the maximum flow rate validated by the microbial retention study. The sponsor agreed to implement pressure monitoring of the sterile filtration process and to set a maximum pressure limit. Current expectations for monitoring and control of sterilizing filtration processes in such cases are being developed. 12
13 Microbial Retention Validation: Common Deficiencies Retention study report and viability data not provided in addition to the summary data, or the study report was not legible. Scaled-down study parameters were not compared to production parameters, or the scaled-down study did not support the worst-case production parameters. Product contact time, flow rate or pressure, product volume per unit of membrane surface area, temperature. 13
14 Microbial Retention Validation: Common Deficiencies (cont.) Inadequate justification for not performing the study as a single-stage direct challenge with unmodified product under worst-case conditions. The drug product formulation was bactericidal to the challenge organism under the conditions of the study, so water was used as a surrogate solution. The study design was modified to accommodate an unnecessarily long filtration time limit. 14
15 Microbial Retention Validation: Case Study 1 Issue: The microbial retention study was performed as a two-stage test: product conditioning followed by bacterial challenge. The challenge organism (B. diminuta) was suspended in water because the drug product formulation was bactericidal to B. diminuta. In this case, the proposed time limit for production filtration was reasonable. The challenge organism was not viable in the drug product formulation for the full duration of the proposed time limit. Performance of a two-stage test was justified. However: In general, water is not a suitable surrogate solution for BLA products. Studies were not performed to identify the bactericidal component of the product or process, which would allow for a more suitable study design. 15
16 PMC: Microbial Retention Validation: Case Study 1 (cont.) The microbial retention study was done with purified water as a surrogate solution for the drug product. Perform a repeat microbial retention study for the sterilizing filter using a suitable surrogate solution. Product attributes of the surrogate solution that are known to affect microbial retention (surface tension, viscosity, ionic strength, etc.) should model the drug product as closely as possible while preserving viability of the challenge organism. Alternatively, a reduced exposure time approach may be appropriate. 16
17 Microbial Retention Validation: Case Study 2 Issue: The microbial retention study was performed as a two-stage test: product conditioning followed by bacterial challenge with B. diminuta suspended in unmodified product. Result: The proposed time limit for filtration was 7 days. The maximum filtration time for the process validation lots was ~ 2 days. The proposed filtration time limit was much longer than that needed for production. The risk of microbial penetration of the filter increases with time. The time limit for filtration was lowered to ~ 3.5 days based on the bacterial challenge stage of the microbial retention study. 17
18 Common Deficiencies and Case Studies Sterilizing filtration Post-reconstitution and post-dilution storage Microbial challenge studies Media fills 18
19 Post-Reconstitution and Post-Dilution Storage Lyophilized products are reconstituted prior to administration, as directed in the label. Proposed post-reconstitution storage time should be supported by microbial challenge studies to demonstrate that the product does not support microbial growth under the proposed storage conditions. This requirement also applies to post-dilution storage times for liquid or reconstituted products. 19
20 Post-Reconstitution and Post-Dilution Storage Studies To support a post-reconstitution or post-dilution storage time: Challenge studies should be conducted using a panel of microorganism provided in the USP<51> (Antimicrobial Effectiveness Testing) plus typical skin flora or species associated with hospital-borne infections. Challenge levels should be less than 100 CFU/mL. Temperature(s) described in the proposed product s labeling should be tested. Test should be conducted for twice the recommended storage period and use the label-recommended diluent(s). No increase from the initial counts is defined as less than 0.5 log 10 unit higher than the initial inoculum. 20
21 Post-Dilution Storage: Case Study 1 Initial labeling: Product A is diluted in 0.9% NaCl prior to administration. Proposed post-dilution storage conditions: up to 24 hours at 2-8 C or up to 12 hours at C. Growth promotion study results: Growth-promoting for P. aeruginosa: By 32 hours at 2-8 C By 24 hours at C Growth-promoting for E. coli: By 16 hours at C Labeling revision: Two-fold increase in CFU at the 12 hour time point (duplicate samples) Storage at C was removed from the labeling. 21
22 Post-Dilution Storage: Case Study 2 Initial labeling: Product B is diluted in 0.9% NaCl prior to administration. The infusion time, which is based on patient tolerance of the drug, is hours. Labeling stated that room temperature diluted solution should be used within 24 hours of preparation. The sponsor was asked to include the hour infusion time in the growth promotion study design. Study results: product was growth-promoting for P. aeruginosa and E. coli. Both were TNTC at the first time point (24 hours) at 25 C and 30 C Review actions: Labeling revision: post-dilution storage for not more than 4 hours at 2-8 C prior to administration. Risk was communicated to clinical reviewers. 22
23 Common Deficiencies and Case Studies Sterilizing filtration Post-reconstitution and post-dilution storage Media fills Media fill program information Media fill data 23
24 Media Fills: Common Deficiencies Relevance of media fill information and data to the Product X manufacturing process was not clearly explained. Insufficient detail and justification regarding the media fill conditions (e.g., line speed, number of vials filled, inspected, rejected or discarded and incubated). Maximum hold times were not validated. Summaries of environmental and personnel monitoring data from the media fills were not provided. Growth promotion studies were incomplete or not provided. Contaminating microorganisms were not identified Acceptance criteria for media fills were not provided. No plans for action to be taken following a media fill failure. 24
25 Media Fills: Case Study Media fill information provided in the original BLA submission: The [ Product X ] manufacturing process is covered by [the drug product manufacturer s] routine bracketed media fill process, which is regularly validated. Minimal information about the media fill program. Minimal data from only one media fill. Data from the three most recent fills or from the initial qualification + more recent fills should be provided. 25
26 Media Fills: Case Study (cont.) Media fill program information that was provided in the BLA is underlined: Requalification frequency Requalification strategy Matrix approach, bracketing approach, etc. How does the requalification strategy apply to Product X manufacturing? Procedures used to simulate any steps of a normal production fill Lyophilization, hold times, etc. Are the manufacturing process steps for Product X covered? 26
27 Media Fills: Case Study (cont.) Media fill program information that was provided in the BLA is underlined (cont): How do media fills provide a worst-case challenge for aseptic processing operations? Interventions, duration, number of personnel, etc. How are the media fill parameters worst-case compared to the production parameters for Product X manufacturing? Acceptance criteria for media fills Actions taken when media fills fail Investigations and microbial ID Product disposition 27
28 Media Fills: Case Study (cont.) Data provided in the BLA for one media fill is underlined: Identification of aseptic filling area and fill line Identification of container-closure system (type, size, etc.) Type of medium and fill volume Date of the fill, total time for the fill, number of units filled, and number of units incubated Number of units filled but not incubated (and reasons for exclusion) Number of positive units Media fill process parameters (compare to production parameters for the BLA product) Production steps simulated and interventions performed Incubation parameters for filled units (time, temperature, container orientation) Growth promotion test procedures and test results for the medium Environmental and personnel monitoring results (number of samples, excursions, microbial ID) In addition to the data above, the media fill reports may also be requested 28
29 Media Fills: Case Study (cont.) Filing deficiency: Insufficient relevant information provided on the media fill program, including media fill acceptance criteria and action taken in the event of a failure. Insufficient information on the aseptic processing operations relevant to Product X to enable a substantive and meaningful review. 29
30 Conclusions Sterilizing filtration: Integrity testing information and data should be provided. Filtration parameters should be supported by the microbial retention study. Modifications to the microbial retention study design should be made only when necessary and should be supported by viability study data. Post-reconstitution and post-dilution storage conditions indicated in the labeling should be supported by growth promotion study data. 30
31 Conclusions (2) Media fill data should be explained in the context of the product under review, and sufficient information should be provided. Refer to the guidance documents and pre-meeting comments for the drug product information that should be included in your BLA. FDA review timelines are based on the expectation that applications are complete at the time of submission. 31
32 Acknowledgements Lynne Ensor, Ph.D. Director (Acting) Division of Microbiology Assessment Patricia Hughes, Ph.D. Branch Chief (Acting) Division of Microbiology Assessment 32
33 Reference: Drug Product Micro Content for CDER BLAs Provide the following information in section 3.2.P.3.3 and/or 3.2.P.3.4, as appropriate: Description of the manufacturing areas and fill line, including air classifications. Description of the environmental and personnel monitoring programs. Sterilization and depyrogenation process parameters for equipment and components that contact the sterile drug product, unless referenced in Drug Master Files. Description of the sterilizing filter (supplier, membrane material, membrane surface area, etc.), the pressure limit or flow rate limit for sterilizing filtration, and the acceptance criterion for post-use integrity testing. Parameters for filling, stoppering, and capping. Processing and hold time limits, including the time limit for sterilizing filtration. Bioburden and endotoxin limits. 33
34 Reference: Drug Product Micro Content for CDER BLAs Provide protocols and reports with validation data in section 3.2.P.3.5: Bacterial filter retention study for the sterilizing filter. Three successful consecutive product intermediate hold time validation runs at manufacturing scale. Bioburden and endotoxin levels before and after the maximum allowed hold time should be monitored and bioburden and endotoxin limits provided. Sterilization and depyrogenation of equipment and components that contact the sterile drug product. Provide summary data for the three most recent requalification studies and describe the equipment requalification program. Note that this requirement includes disposable filtration/filling assemblies and storage bags which are supplied ready to use. For information located in Drug Master Files (DMFs), provide Letters of Authorization which list the relevant depyrogenation and sterilization sites and which clearly identify the location of the relevant information within the DMF. (continued on the next slide) 34
35 Reference: Drug Product Micro Content for CDER BLAs Provide protocols and reports with validation data in section 3.2.P.3.5: (continued from the previous slide) Three successful consecutive media fill runs, including summary environmental and personnel monitoring data obtained during the runs. Isolator decontamination, if applicable. Maintenance of container closure integrity during production (vial capping, syringe or autoinjector assembly, etc.). Summary of shipping validation studies and data. For pre-filled syringes, the effects of varying air pressure on plunger movement and potential breaches to the integrity of the sterile boundary during shipment should be addressed. Include data that demonstrate that plunger movement during air transportation does not impact product sterility. 35
36 Reference: Drug Product Micro Content for CDER BLAs Provide drug product testing information and data in the appropriate sections of Module 3: Verification of the bioburden, sterility and endotoxin test methods performed for in-process intermediates (if applicable) and the drug product, as appropriate. In addition, the test methods should be described. Rabbit Pyrogen Test conducted on three batches of drug product in accordance with 21 CFR (b). Low endotoxin recovery studies. The effect of hold time on endotoxin recovery should be assessed by spiking a known amount of endotoxin standard (CSE or RSE) into undiluted drug product and testing for recoverable endotoxin over time. Container closure integrity testing information and data. Container closure integrity method validation should demonstrate that the assay is sensitive enough to detect breaches that could allow microbial ingress. Container closure integrity testing should be performed in lieu of sterility testing for stability samples every 12 months (annually) and at expiry. 36
Updates Regarding the OGD Division of Microbiology & ANDA Sterility Assurance Review Dr. Lynne A. Ensor
Updates Regarding the OGD Division of Microbiology & ANDA Sterility Assurance Review Dr. Lynne A. Ensor U.S. Food & Drug Administration Center for Drug Evaluation & Research Office of Pharmaceutical Science/Office
More informationGuidance for Industry
Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products Center for Drug Evaluation and Research (CDER) Center
More informationAnnex A2. Guidance on Process Validation Scheme for Aseptically Processed Products
Annex A2 Guidance on Process Validation Scheme for Aseptically Processed Products 1 Table of content 1 PURPOSE... 3 2 SCOPE... 3 3 GENERAL INFORMATION... 3 4 INFORMATION NEEDED FOR ASEPTIC PROCESSES VALIDATION...
More informationRisk based approaches for a sterility assurance application review: a microbiologist s perspective Dr. Yeissa Chabrier Roselló
Risk based approaches for a sterility assurance application review: a microbiologist s perspective Dr. Yeissa Chabrier Roselló Product Quality Microbiologist Division of Microbiology Assessment Office
More informationGuidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE
Guidance Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and
More informationOverview of Inspection Issues with Legacy Products
Overview of Inspection Issues with Legacy Products Presented by Simone E. Pitts Consumer Safety Officer, USFDA Team Biologics simone.pitts@fda.hhs.gov Objective To provide some examples of recent inspectional
More informationFDA s Guidance for Industry
Sterile Drug Products Produced by Aseptic Processing - CGMPs Midwest FDC Conference November 4 2005 Susan Bruederle, Investigator FDA / ORA / Central Region Chicago District / Hinsdale IL FDA s Guidance
More informationAllergy Laboratories, Inc. 10/4/13
Allergy Laboratories, Inc. 10/4/13 SEP 04, 2013 Department of Health and Human Services Public Health Service Food and Drug Administration Office of Regulatory Affairs 12420 Parklawn Drive ELEM-2152 Rockville,
More informationValidation of Sterilizing Grade Filters
Validation of Sterilizing Grade Filters Presented by Laura Okhio-Seaman Sartorius Corporation 1 Sterilizing Grade Filters The definition of a sterilizing grade filter is one that will produce a sterile
More informationHow do you know the drug you are using is safe and effective?
The Chemistry, Manufacturing, and Controls (CMC) Technical Section: The Big Picture of a Long-term Commitment AAVPT Workshop February 28, 2011 James K. Nitao, Ph.D. Biotherapeutics Team Division of Manufacturing
More informationMicrobiological Quality of Drug Products after Penetration of the Container System for Dose Preparation Prior to Patient Administration
Microbiological Quality of Drug Products after Penetration of the Container System for Dose Preparation Prior to Patient Administration John W. Metcalfe, Ph.D. Senior Review Microbiologist FDA/CDER/OPS/New
More informationValidation Needs for Sterilization by Aseptic Filtration
Validation Needs for Sterilization by Aseptic Filtration DCVMN Workshop, Hyderabad, 4-8 April 2016 Ramesh Raju Associate Director - Provantage Validation Services Overview Key Regulatory and Industry guidelines
More informationReview Validation of aseptic processes for pharmaceuticals
OPEM www.opem.org Oriental Pharmacy and Experimental Medicine 2010 10(4), 231-238 DOI 10.3742/OPEM.2010.10.4.231 Review Validation of aseptic processes for pharmaceuticals Lincy Joseph*, Mathew George
More informationOverview of a sterility assurance program for PET drugs
Coalition for PET Drug Approval Radiopharmaceutical Sciences Council Overview of a sterility assurance program for PET drugs Eric Webster, PETNET Solutions Disclosures Employee of PETNET Solutions, a Siemens
More informationWhy Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services
Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services Disclosures I, Ross Caputo, declare no conflicts of interest, real or apparent, and
More informationQuestion-based Review (QbR)
Question-based Review (QbR) Rebecca L. Owen, Ph.D. Team Leader, Feed/Topical Team Division of Manufacturing Technologies ONADE/CVM/FDA Outline Background on CMC Filing Requirements What is QbR? QbR at
More informationSeptember 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
September 2, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA Draft Guidance: Current Good Manufacturing Practice Interim
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Celltex Therapeutics Corporation
More informationPDA: A Global. Association. Matrix Approach to Media Fills. (c) 2012 Catalent Pharma Solutions. All rights reserved.
PDA: A Global Matrix Approach to Media Fills Association (c) 2012 Catalent Pharma Solutions. All rights reserved. Overview Guidance Overview Matrix Introduction Why Matrix Media Fills Sample Matrix New
More informationSubpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.
FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis
More informationComplaints Investigations Root Cause Analysis
Complaints Investigations Root Cause Analysis Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does
More informationGuidance for Industry
Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationGuidance for Industry
Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics Additional copies of this guidance are available from the Office of Communication, Training and Manufacturers Assistance
More informationCleaning validation of cleanrooms and preparation equipments
Cleaning validation of cleanrooms and preparation equipments Dr Farshid SADEGHIPOUR Head of production Central Pharmacy, Geneva University Hospitals EAHP Foundation Seminar: Patient Safety; More About
More informationAseptic Process Validation
Aseptic Process Validation IMB GMP Information Seminar 27 th September 2012 Gerard Sheridan, Inspector Date Insert on Master Slide Slide 1 Overview Guidance Best Practices Common Deficiencies Slide 2 Aseptic
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationEstablished Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry
Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationErin Patton, MS Senior Product Specialist Charles River Labs, Microbial Solutions
Validation of a Rapid Microbial Method Approach to Validation Case Studies: Equivalence Verification of an Alternate Assay for Microbial Limits Screening and Sterility Testing of Pharmaceutical Products
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationPorton Biopharma Limited 1/17/17
Porton Biopharma Limited 1/17/17 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS Warning Letter 320 17 19 Return Receipt Requested January 19, 2017 Dr. Roger J. Hinton Managing Director Porton
More informationStudy Summary. Results: All tested media-filled vials were negative for growth of any microorganisms.
A 7 Days Microbial Ingress Test of Single Use Vials Utilizing the EQUASHIELD Closed System Drug Transfer Device Study by Nelson Laboratories (Salt Lake City, UT) 2013, updated in 2014* Study Summary Abstract:
More informationEmcure Pharmaceuticals Limited 3/3/16
1 of 7 05/06/2016 8:22 AM U.S. Food and Drug Administration Protecting and Promoting Your Health Emcure Pharmaceuticals Limited 3/3/16 Department of Health and Human Services Public Health Service Food
More informationA Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products
A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products Angela Whatley, Ph.D. Office of Tissues and Advanced Therapies CBER/FDA CMC Strategy Forum on Cell & Gene Therapies
More informationThe Application of Pharmaceutical cgmp to Live Bacterial Products. James Harris Business Development Manager
The Application of Pharmaceutical cgmp to Live Bacterial Products James Harris Business Development Manager The Objective CMC expectations of a cgmp live bacterial biopharmaceutical project Overview Define
More informationINTERNATIONAL STANDARDS ON FLUID PREPARATION FOR CONVECTIVE THERAPIES. Richard A. Ward, Ph.D.
INTERNATIONAL STANDARDS ON FLUID PREPARATION FOR CONVECTIVE THERAPIES Richard A. Ward, Ph.D. THE EVOLUTION OF CONVECTIVE THERAPIES Convective therapies enhance large molecule removal by using ultrafiltration
More informationANNEX 1: COMMENT SUBMISSION DOCUMENT
Submission Comments on: GMP Annex 1: Proposal for amendments to the environmental classification table for particles and associated text, amendment to section 42 concerning acceptance criteria for media
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationUS FDA: CMC Issues for INDs
ISBTC Global Regulatory Summit October 29, 2008 US FDA: CMC Issues for INDs Keith Wonnacott, Ph.D. keith.wonnacott@fda.hhs.gov US Food and Drug Administration Center for Biologics Evaluation and Research
More informationMicrobiological Cleaning Method Validation
Microbiological Cleaning Method Validation The purpose of cleaning procedures should never be to reduce bioburden to an acceptable level! Fergus O Connell QA Manager Eurofins ams Laboratories www.eurofins.com
More informationCBER Expectations Regarding Contract Manufacturing
CBER Expectations Regarding Contract Manufacturing LCDR Qiao Bobo, Ph.D. FDA/CBER/OCBQ/DMPQ CASSS CMC Strategy Forum Summer 2014 Outline 2 Types of Cooperative Manufacturing Arrangements CBER Expectations
More informationThe FDA Just Arrived... Are You Ready? Presented By Sandra Lueken Sr. Director, Quality AstraZeneca Biologics
The FDA Just Arrived... Are You Ready? Presented By Sandra Lueken Sr. Director, Quality AstraZeneca Biologics Objectives Review Quality Systems Audit Approach and cgmp fundamentals Logistical Audit Preparation
More informationTests to Support Sterility Claim. Imtiaz Ahmed
Tests to Support Sterility Claim Imtiaz Ahmed Sterile Product As per TGO 77, a sterile product must comply with the requirements of the following tests: Sterility Test Bacterial Endotoxins Test Appendix
More informationPhase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017
Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/
More informationMicrobiology Testing: USP requirements for Sterile and Nonsterile Preparations Webinar Q&A
USP Antimicrobial Effectiveness Testing Microbiology Testing: Webinar Q&A 1. If a base ingredient is designed for the purpose of compounding a specific type of preparation does this forgo the necessity
More informationExtending Beyond Use Dating for Compounded Preparations Webinar Q&A
Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific
More informationExtending Beyond Use Dating for Compounded Preparations Webinar Q&A
Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific
More informationMetrics in Microbiology Monitoring Practices
Metrics in Microbiology Monitoring Practices Crystal Booth, M.M. Masters of Microbiology from North Carolina State University Former Associate Director of Microbiology at Novartis Metrics in Microbiology
More informationQuality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 Inspections, Compliance, Enforcement, and Criminal Investigations Lupin Limited 5/7/09 Department of Health and Human Services Public Health Service Food and Drug Administration CENTER FOR
More informationAdvancements on implementation of single use technology in vaccine manufacturing
Advancements on implementation of single use technology in vaccine manufacturing October 25 th, 2013 DCVMN Meeting Rio de Janeiro, Brazil Outline Overview of single use products Applications of single
More informationHow to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER
How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco
More informationDelivery of materials (usually finished product from a distribution center) to a first paying customer external to Site
Title: Cold Chain Management of Biopharmaceutical Materials Guidance Number: 122 Prepared by: Date: Supersedes: Checked by: Date: Date Issued: Approved by: Date: Review Date: Introduction The risk of compromising
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Thomas E. Young,
More informationMedia Fill A Process Simution. Presented By Shikha Chauhan
Media Fill A Process Simution Presented By Shikha Chauhan 21 CFR 211.113 Validation of Aseptic Processing and Sterilization Process Simulation / Media Fill Filtration Efficacy Sterilization of Equipment,
More informationIDT Australia Ltd. 5/23/18
IDT Australia Ltd. 5/23/18 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS Warning Letter 320-18-55 Return Receipt Requested May 23, 2018 Dr. Graeme R. Kaufman CEO, Acting, and Chairman of the
More informationCell Therapy Product Manufacturing Considerations. July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D.
Cell Therapy Product Manufacturing Considerations July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D. Office of Tissues and Advanced Therapies FDA/CBER Overview Establishing Manufacturing Control Applying
More informationOverview of Generic PET Applications. Sema Basaran, Ph.D. The 34 th Annual High Country Nuclear Medicine Conference.
Overview of Generic PET Applications Sema Basaran, Ph.D. The 34 th Annual High Country Nuclear Medicine Conference. March 1-6, 2013 Disclaimer This presentation reflects the views of the presenter and
More informationProposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding <823>
Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding Ravi Ravichandran, Ph.D. Steve Zigler, Ph.D. February 21, 2011 Agenda Rationale for the
More informationCompounding Pharmacies and the USP <71> Sterility Tests
Compounding Pharmacies and the USP Sterility Tests Scott Sutton, Ph.D. scott.sutton@microbiol.org 49 41 Disclaimer I am making this presentation as an independent agent I am not making this presentation
More informationfor IND and RDRC Regulated PET Compounding
Overview of USP Chapter for IND and RDRC Regulated PET Compounding Distributed Manufacturing of PET Radiopharmaceuticals for Multi-Center Clinical Trials SNM, Annual Meeting Toronto, Ontario, Canada
More informationVaccine Assessment for Prequalification and Programmatic Suitability for Prequalification
Vaccine Assessment for Prequalification and Programmatic Suitability for Prequalification Dr Drew Meek Prequalification Team/Vaccines Assessment Regulation of Medicines and other Health Technologies World
More informationFDA's Perspectives on Cross- Contamination in CMO Facilities, Considering High Risk Products
FDA's Perspectives on Cross- Contamination in CMO Facilities, Considering High Risk Products Bo Chi, Ph.D. Biotech Manufacturing Assessment Branch DGMPA/OMPQ/OC/CDER 1 Outline Regulatory framework Regulatory
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Seite 1 von 10 Inspections, Compliance, Enforcement, and Criminal Investigations Laboratoire Atlas Inc. 6/25/09 hhsbluebird Department of Health and Human Services Public Health Service Food and Drug Administration
More information2-2 Sterile Product Assessment. Satish Mallya Ph.D Training Workshop CPH, May 2015
2-2 Sterile Product Assessment Satish Mallya Ph.D Training Workshop CPH, May 2015 Focus Overview of Regulatory Requirements Tips for Critical Thinking Issues and Solutions Regulatory Requirements - Overview
More informationData Integrity Issues & Concerns PDA Meeting Kansas City, MO August 21, 2017
Data Integrity Issues & Concerns PDA Meeting Kansas City, MO August 21, 2017 CAPT Sharon K. Pederson (Thoma), PharmD National Expert of Pharmaceutical Inspections Food and Drug Administration ORA/OMPTO/OPQO/DPQP/Pharmaceutical
More informationMINIMUM REQUIREMENTS FOR A VENDOR
MINIMUM REQUIREMENTS FOR A VENDOR When outsourcing the production of sterile products the first step in vendor evaluation is to see if they meet the minimum requirements. We ve developed a group of questions
More informationSan Jose, California, USA
Glisland, Inc. San Jose, California, USA http://www.glisland.com Welcome to the Drug GMP World Current Good Manufacturing Practice cgmp ICH Q10 Pharmaceutical Quality System PQS GMP QSR Quality System
More informationMicrobiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical
Microbiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical RIGHT S O L U T I O N S RIGHT PARTNER Contents TGO 77 - Introduction Tests Performed
More informationFOOD AND DRUG ADMINISTRATION COMPLIANCE PROGRAM GUIDANCE MANUAL PROGRAM M
CHAPTER 56 -- DRUG QUALITY ASSURANCE SUBJECT: Inspections of Licensed Biological Therapeutic Drug Products *Revision note: This program is being reissued as a CDER program due to the transfer of certain
More informationQ8 Pharmaceutical Development
Q8 Pharmaceutical Development For questions regarding this draft document contact (CDER) Ajaz Hussain at 301-594-2847 or (CBER) Christopher Joneckis at 301-435-5681. This draft guidance, when finalized,
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Seite 1 von 10 Inspections, Compliance, Enforcement, and Criminal Investigations Dabur Oncology PLC hhsbluebird Department of Health and Human Services Warning Letter Public Health Service Food and Drug
More informationDrug, Device and Diagnostic Manufacturing
Drug, Device and Diagnostic Manufacturing The Ultimate Resource Handbook Second Edition by Carol DeSain Table of Contents I. BIOMEDICAL RESEARCH AND DEVELOPMENT 1 A. Biomedical Research/Design 4 1. Identification
More informationRegulatory Approval of Modern Gene-Based Cancer Immunotherapies CAR T Cells A product perspective
Regulatory Approval of Modern Gene-Based Cancer Immunotherapies CAR T Cells A product perspective ASQ509 Biomed/Biotech SIG 2/1/18 Xiaobin Victor Lu Division of Cellular and Gene Therapies Office of Tissues
More informationPublic Health Service Food and Drug Administration Silver Spring, MD WARNING LETTER VIA UPS WL:
Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring, MD 20993 WARNING LETTER VIA UPS WL: 320-16-04 December 17, 2015 Mr. Avinash Joshi Quality Head
More informationSun Pharmaceutical Industries Ltd. 12/17/15
1 of 7 02/18/2016 11:34 AM U.S. Food and Drug Administration Protecting and Promoting Your Health Sun Pharmaceutical Industries Ltd. 12/17/15 Department of Health and Human Services Public Health Service
More informationIntroduction and Background
Introduction and Background Validation of Biotech Facilities Pacific Biotech Alliance Robert J. Mackey Pacific Biotech Alliance is an established consulting firm in the Pacific Northwest that specializes
More informationPublic Health Service Food and Drug Administration Silver Spring, MD WARNING LETTER VIA UPS WL: December 17, 2015
12/23/2015 1:37 PM 1 of 10 U.S. Food and Drug Administration Protecting and Promoting Your Health Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring,
More informationProduct Testing & Release. PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 4 th /5 th, 2006
Product Testing & Release PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 4 th /5 th, 2006 Product Testing Used to determine Safety, Purity, Identity, Potency, etc. Suitability of
More informationHVAC and Risk Management RACI Meeting 7 th December Agenda. Design. Project Management. Context. Qualification. Construction
HVAC and Risk Management RACI Meeting 7 th December 2011 Dr Stephen Firmer Asia Pacific Consultants Pty Ltd Agenda Context Project Management Design Construction Qualification Routine Control /Potential
More information3. Equipment Cleaning Validation for Active Pharmaceutical Ingredients (APIs) 8. Process Validation for Active Pharmaceutical Ingredients (API)
Title: Good Working Practice Validation Requirements Practice Number: 06 Prepared by: Date: Supersedes: Checked by: Date: Date Issued: Approved by: Date: Review Date: Topics: 1. Biological Test Methods
More informationChange Control Overview
Change Control Overview Kelly Thomas Atlantic Technical and Validation Services Copyright 2014 by Atlantic Technical and Validation Services, LLC. 1 Session Outline Discuss Regulations Governing Change
More informationCMC Strategy Forum Europe 2016
Science-based Development & Licensing of Combination Products Focus on High Concentration Monoclonal Antibody Solutions in Prefilled Syringes or Prefilled Pens Serge Mathonet, Sanofi Global Regulatory
More informationLABORATORY COMPLIANCE
1 LABORATORY COMPLIANCE Jeanne Moldenhauer Vectech Pharmaceutical Consultants, Inc. Farmington Hills, MI INTRODUCTION Implementation of the Systems-Based Inspection Guideline for drug manufacturers in
More informationRanbaxy Laboratories, Ltd., Dewas, India 16-Sep-08
Ranbaxy Laboratories, Ltd., Dewas, India 16-Sep-08 Department of Health and Human Services Public Health Service Food and Drug Administration White Oak, Bldg. 51 Silver Spring, MD 20993 Warning Letter
More informationStrategies for IND Filing Success: Chemistry, Manufacturing and Controls
Strategies for IND Filing Success: Chemistry, Manufacturing and Controls October 21, 2016 Presented by: Sharon Ayd, Ph.D., MBA Chief Scientific Officer and SVP, Pharmaceuticals document contains proprietary
More information21CFR Ventilation, air filtration, air heating and cooling. 21CFR211 Details, Details. 21CFR Equipment Cleaning and Maintenance
21CFR211 Details, Details Kirsten L. Vadheim, Ph.D., RAC 7710 196th Avenue N.E. Redmond WA 98053 Tel: 651.260.6560 Fax: 425.868.4302 klvadheim@hotmail.com 21CFR211.46 Ventilation, air filtration, air heating
More informationDocumenta tion and Records
Documenta tion and Records Page 1 of 30 Training Outcome of the Module: After completing this module, you will be able to: Recognize the importance of procedures Recognize the importance of record keeping
More informationPDA Technical Report #26:
PDA Technical Report #26: Implications on Liquid Filter Validation Maik W. Jornitz, Sartorius Corp. Filter Qualification Tests for internal Validation Guides Physical Tests flow rates/delta p throughput
More informationHISTORY AND MILESTONES
HISTORY AND MILESTONES HISTORY AND MILESTONES DOC S.r.l., Documentation Organization & Consultancy, was established in 1997 by MASCO group C.E.O. Eng. Alberto Borella and Eng. Paolo Curtò who became Managing
More informationOverview and Introduction Annex 1 Revision
Overview and Introduction Annex 1 Revision Paul Moody, Inspector Pharmig Current Hot Topics in Pharmaceutical Microbiology, Dublin May 30 th, 2018 Scope History Process of Revision Rationale for Revision
More informationHow to Select a Microbiology Contract Testing Laboratory? Tony Cundell, Ph. D. Microbiological Consulting, LLC Scarsdale, New York
How to Select a Microbiology Contract Testing Laboratory? Tony Cundell, Ph. D. Microbiological Consulting, LLC Scarsdale, New York June 13, 2017 IVT Microbiology Week 1 Presentation Overview Rationale
More informationInspection Trends. American Society for Quality Richmond, VA Section March 8, 2016
Inspection Trends American Society for Quality Richmond, VA Section March 8, 2016 Brooke K. Higgins, Senior Policy Advisor CDER / Office of Compliance Office of Manufacturing Quality Division of Drug Quality
More informationRisk Assessments for Host Cell Protein Control Strategies: CDER Experiences
Risk Assessments for Host Cell Protein Control Strategies: CDER Experiences Laurie Graham FDA/CDER Office of Pharmaceutical Quality (OPQ) Office of Policy for Pharmaceutical Quality (OPPQ) 1 Disclaimer
More informationBen Venue Laboratories, Inc. 16-Nov-07
Ben Venue Laboratories, Inc. 16-Nov-07 Department of Health and Human Services Public Health Service Food and Drug Administration Cincinnati District Office Central Region 6751 Steger Drive Cincinnati,
More informationGuidelines for Process Validation of Pharmaceutical Dosage Forms
Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical
More informationIndustry Case Study: A Microbial Investigation of Contamination by Burkholderia multivorans. Jim Klein and Geert Verdonk Merck & Co., Inc.
Industry Case Study: A Microbial Investigation of Contamination by Burkholderia multivorans Jim Klein and Geert Verdonk Merck & Co., Inc. Messages The role of microbiological analysis The role of subject
More informationProduct Testing & Release. PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 10 th /11 th, 2007
Product Testing & Release PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 10 th /11 th, 2007 Product Testing Used to determine Safety, Purity, Identity, Potency, Quality Suitability
More informationCMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C.
CMC Considerations for 505(b)(2) Applications Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C. October 2011 1 Introduction Outline Brief overview of FDA drug approval pathways
More information3M Purification Inc. Technical and Scientific Services Global Support for the Life Science Industry. Global Expertise delivered locally
3M Purification Inc. Technical and Scientific Services Global Support for the Life Science Industry Global Expertise delivered locally Global expertise delivered locally As a global leader in measuring,
More informationThe Parenteral Drug Association
C O N F E R E N C E R E P O R T Equipment Cleaning Microbial Control Issues By Destin A. LeBlanc, M.A. Cleaning Validation Technologies Validation: The Parenteral Drug Association (PDA) spring conference
More information